Lupin Share Price
2110.00-22.00 (-1.03%)
+8.14% past 1 Year
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in many markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products,
Corporate filings & documents
Announcements
ESG Rating by Crisil ESG Ratings & Analytics Ltd.
1 week agoESG Rating by Crisil ESG Ratings & Analytics Ltd.
1 week agoIntimation of allotment of 30967 equity shares under ESOP.
1 week agoIntimation of allotment of 30967 equity shares under ESOP.
1 week agoESG Rating by ESG Risk Assessment and Insights Limited.
1 week agoESG Rating by ESG Risk Assessment and Insights Limited.
1 week agoVISUfarma B.V. the Netherlands a wholly owned subsidiary of the Company has entered into an Exclusive License Agreement with Visus Therapeutics Inc. U.S.A.
2 weeks agoVISUfarma B.V. the Netherlands a wholly owned subsidiary of the Company has entered into an Exclusive License Agreement with Visus Therapeutics Inc. U.S.A.
2 weeks agoIntimation of Demise of Dr. Sofia Mumtaz President Legal & Compliance Canada ANZ & NEA Business a Senior Management Personnel of the Company.
2 weeks agoIntimation of Demise of Dr. Sofia Mumtaz President Legal & Compliance Canada ANZ & NEA Business a Senior Management Personnel of the Company.
2 weeks agoLupin Announces Approval from U.S. FDA for Pitolisant Tablets.
2 weeks agoLupin Announces Approval from U.S. FDA for Pitolisant Tablets.
2 weeks agoTranscript of Q1 FY2027 Earnings Conference Call
3 weeks agoTranscript of Q1 FY2027 Earnings Conference Call
3 weeks agoLupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
3 weeks agoLupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
3 weeks agoIntimation about participating in the Analyst/Institutional Investors Meet.
3 weeks agoIntimation about participating in the Analyst/Institutional Investors Meet.
3 weeks agoCopies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30 2026.
3 weeks agoCopies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30 2026.
3 weeks agoLink of Audio recording of the Earnings Call-Q1 FY27.
3 weeks agoLink of Audio recording of the Earnings Call-Q1 FY27.
3 weeks agoInvestor Presentation (Revised) - Q1 FY27 Results
4 weeks agoInvestor Presentation- Q1 FY2027
4 weeks agoInvestor Presentation- Q1 FY2027
4 weeks agoLupin Q1 FY2027 Results
4 weeks agoLupin Q1 FY2027 Results
4 weeks agoBoard Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
4 weeks agoBoard Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
4 weeks agoApproval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
4 weeks agoApproval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
4 weeks agoDetails of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizers Report.
1 month agoDetails of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizers Report.
1 month agoProceedings of the Forty-Fourth Annual General Meeting held on August 04 2026.
1 month agoProceedings of the Forty-Fourth Annual General Meeting held on August 04 2026.
1 month agoLupin Announces the approval of Diazepam Injection USP in the United States.
1 month agoLupin Announces the approval of Diazepam Injection USP in the United States.
1 month agoLupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.
1 month agoLupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.
1 month agoSchedule of Earnings Call for Q1 FY27
1 month agoSchedule of Earnings Call for Q1 FY27
1 month agoLupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30 2026.
1 month agoLupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30 2026.
1 month agoLupin Inc. U.S.A. wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332 000 Common Shares of Kaveri Therapeutics Inc. U.S.A.
1 month agoLupin Inc. U.S.A. wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332 000 Common Shares of Kaveri Therapeutics Inc. U.S.A.
1 month agoCopy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.
1 month agoCopy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.
1 month agoLupin Recognized Among Indias Best Employers in the Nation-Builders Category by Great Place to Work India 2026.
1 month agoLupin Recognized Among Indias Best Employers in the Nation-Builders Category by Great Place to Work India 2026.
1 month agoBusiness Responsibility and Sustainability Report of the Company for FY 2025-26.
1 month agoConcalls & investor presentations
Aug 2026
ConcallPresentation
Aug 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Feb 2025
Nov 2024
ConcallPresentation
Nov 2024
ConcallPresentation
Aug 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Nov 2023
ConcallPresentation
Nov 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Oct 2021
ConcallPresentation
Oct 2021
ConcallPresentation
Aug 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
Jan 2021
ConcallPresentation
Jan 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-07-17
Dividend
18.0
2025-07-25
Dividend
12.0
2024-07-16
Dividend
8.0
2023-07-14
Dividend
4.0
2022-07-14
Dividend
4.0
2021-07-27
Dividend
6.5
2020-08-03
Dividend
6.0
2019-07-29
Dividend
5.0
2018-07-30
Dividend
5.0
2017-07-24
Dividend
7.5
2016-07-25
Dividend
7.5
2015-07-14
Dividend
7.5
2014-07-21
Dividend
3.0
2014-02-13
Dividend
3.0
2013-07-29
Dividend
4.0
2012-07-13
Dividend
3.2
2011-07-18
Dividend
3.0
2010-08-27
Split
10:2
2010-07-19
Dividend
13.5
Company details
Registered office
Kalpataru Inspire, 3rd Floor Off. Western Express Highway Santacruz (East) Mumbai Maharashtra PIN: 400055 Tel No: 022 66402323 Fax No: 022 66408131 Email: [email protected] Internet: www.lupin.com
Registrars
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra C 101, 247 Park LBS Marg Vikhroli (West) PIN: Tel No: +91 810 811 8484 Fax No: 91-022-49186060 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Amit Kumar Gupta, Company Secretary & Compliance Officer
Manju D Gupta, Chairperson
Nilesh Gupta, Managing Director
Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU
Jeffrey Kindler, Non Executive Independent Director
Anand Kripalu, Non Executive Independent Director
Punita Lal, Non Executive Independent Director
K B S Anand, Non Executive Independent Director
Mark D McDade, Non Executive Independent Director
Alfonso Zulueta, Non Executive Independent Director
Details
BSE 500257
NSE LUPIN
ISIN INE326A01037